Cargando…

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose

Background: The effects of various dosages and treatment regimens on intravitreal aflibercept concentrations and the proportion of free vascular endothelial growth factor (VEGF) to total VEGF were evaluated using a drug and disease assessment model. The 8 mg dosage received specific attention. Metho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veritti, Daniele, Sarao, Valentina, Di Bin, Francesco, Lanzetta, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220677/ https://www.ncbi.nlm.nih.gov/pubmed/37242658 http://dx.doi.org/10.3390/pharmaceutics15051416

Ejemplares similares

Intravitreal Steroids for the Treatment of Retinal Diseases
por: Sarao, Valentina, et al.
Publicado: (2014)

Anti-VEGF Drugs Dynamics: Relevance for Clinical Practice
por: Veritti, Daniele, et al.
Publicado: (2022)

The ideal intravitreal injection setting: office, ambulatory surgery room or operating theatre? A narrative review and international survey
por: Veritti, Daniele, et al.
Publicado: (2023)

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB
por: Avery, Robert L., et al.
Publicado: (2017)

A Propensity-Score Matching Comparison between 27-Gauge and 25-Gauge Vitrectomy Systems for the Repair of Primary Rhegmatogenous Retinal Detachment
por: Veritti, Daniele, et al.
Publicado: (2019)

Optimal Keratoplasty for the Correction of Presbyopia and Hypermetropia
por: Veritti, Daniele, et al.
Publicado: (2017)

Infection control measures in ophthalmology during the COVID-19 outbreak: A narrative review from an early experience in Italy
por: Veritti, Daniele, et al.
Publicado: (2020)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti, Daniele, et al.
Publicado: (2021)

Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
por: Kaiser, Peter K, et al.
Publicado: (2019)

Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression
por: Veritti, Daniele, et al.
Publicado: (2022)

Durability of VEGF Suppression With Intravitreal Aflibercept and Brolucizumab: Using Pharmacokinetic Modeling to Understand Clinical Outcomes
por: Eissing, Thomas, et al.
Publicado: (2021)

A comparison between a white LED confocal imaging system and a conventional flash fundus camera using chromaticity analysis
por: Sarao, Valentina, et al.
Publicado: (2019)

Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye
por: Bertoli, Federica, et al.
Publicado: (2020)

The Present and Future of Optic Pathway Glioma Therapy
por: Dal Bello, Simone, et al.
Publicado: (2023)

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
por: Rodvold, Keith A
Publicado: (2019)

Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
por: Ohji, Masahito, et al.
Publicado: (2020)

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies
por: Finley, Stacey D, et al.
Publicado: (2011)

Color Fundus Autofluorescence to Determine Activity of Macular Neovascularization in Age-Related Macular Degeneration
por: Vujosevic, Stela, et al.
Publicado: (2021)

Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Fundus autofluorescence applications in retinal imaging
por: Gabai, Andrea, et al.
Publicado: (2015)

Erratum to: Clinical Use of Rivaroxaban: Pharmacokinetic and Pharmacodynamic Rationale for Dosing Regimens in Different Indications
por: Trujillo, Toby, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies
por: Laille, Eric, et al.
Publicado: (2015)

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes
por: Trejo Corona, Stephanie, et al.
Publicado: (2023)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti–vascular endothelial growth factor therapy of macular diseases
por: Lanzetta, Paolo, et al.
Publicado: (2017)

Randomized clinical trial comparing intravitreal aflibercept combined with subthreshold laser to intravitreal aflibercept monotherapy for diabetic macular edema
por: Tatsumi, Tomoaki, et al.
Publicado: (2022)

One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
por: Tamachi, Tomoko, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy
por: Le, KN, et al.
Publicado: (2015)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

Intravitreal ziv-aflibercept in diabetic vitreous hemorrhage
por: Mansour, Ahmad M., et al.
Publicado: (2020)

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation
por: Nasu, Risa, et al.
Publicado: (2023)

Experience with the Pascal(®) photocoagulator: An analysis of over 1200 laser procedures with regard to parameter refinement
por: Sheth, Saumil, et al.
Publicado: (2011)

Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
por: Stewart, Michael W
Publicado: (2012)

Pharmacokinetics of Anti‐VEGF Agent Aflibercept in Cancer Predicted by Data‐Driven, Molecular‐Detailed Model
por: Finley, SD, et al.
Publicado: (2015)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration
por: García-Quintanilla, Laura, et al.
Publicado: (2019)

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2021)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lq4g07ijloj15qapfp8sop4iam